Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:DNLI
FechaHoraFuenteTítuloSímboloCompañía
06/06/202415:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
04/06/202417:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
03/06/202407:00GlobeNewswire Inc.Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesNASDAQ:DNLIDenali Therapeutics Inc
31/05/202415:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
07/05/202415:01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/05/202407:00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
01/03/202415:51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
27/02/202407:05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
27/02/202407:00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
07/02/202407:00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
01/02/202407:00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
08/01/202407:00GlobeNewswire Inc.Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNASDAQ:DNLIDenali Therapeutics Inc
27/11/202318:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:DNLIDenali Therapeutics Inc
21/11/202305:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:DNLIDenali Therapeutics Inc
07/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DNLIDenali Therapeutics Inc
07/11/202315:01GlobeNewswire Inc.Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/11/202309:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:DNLIDenali Therapeutics Inc
11/09/202305:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:DNLIDenali Therapeutics Inc
30/08/202307:30GlobeNewswire Inc.Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023NASDAQ:DNLIDenali Therapeutics Inc
29/08/202308:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:DNLIDenali Therapeutics Inc
08/08/202315:01GlobeNewswire Inc.Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
21/06/202305:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DNLIDenali Therapeutics Inc
21/06/202305:00PR Newswire (US)Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule DrugsNASDAQ:DNLIDenali Therapeutics Inc
20/06/202306:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DNLIDenali Therapeutics Inc
20/06/202306:00GlobeNewswire Inc.Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)NASDAQ:DNLIDenali Therapeutics Inc
16/06/202316:37Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:DNLIDenali Therapeutics Inc
16/05/202305:00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:DNLIDenali Therapeutics Inc
08/05/202315:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DNLIDenali Therapeutics Inc
08/05/202315:01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
18/04/202315:08Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

Su Consulta Reciente

Delayed Upgrade Clock